STAT3 and colorectal carcinoma: Hence, the combined treatment of a chemotherapeutic agent with an HDAC6 inhibitor may offer an improved and novel curative approach for CRC patients, especially in those cases where the IL-6/STAT3/FRA1 signaling axis is activated.